EUCTR2011-004964-32-NO进行中（未招募）不适用
A Double-Blind, Randomised, Placebo-Controlled, Parallel-Group, 12-Week Study of Pitavastatin in High-Risk Hyperlipidaemia in Childhood P/266/2011, P267/2011, P268/2011 - PASCAL 401
适应症
相关药物
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 入组人数
- 96
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •1. Male or female =6 years of age and <17 years of age at randomisation;
- •2. Have fasting LDL-C levels =160 mg/dL (4.1 mmol/L) or LDL-C =130 mg/dL (3.4 mmol/L) if any of the following additional risk factors are present:
- •A family history of premature cardiovascular disease defined as a myocardial infarction before age 50 in a second-degree relative or before age 60 in a first-degree relative with at least 1 relative (parent, grandparent, or sibling) affected;
- •Presence of low HDL-C (<45 mg/dL) or high TG (>150 mg/dL);
- •Presence of high lipoprotein(a) (>75 nmol/L);
- •09 December 2011 vii12
- •Presence of type 2 diabetes mellitus diagnosed by treating physician according to current guidances; or
- •Presence of hypertension defined as systolic and diastolic blood pressures above the 95th percentile for age and size;
- •3. Have not taken any lipid-lowering medications in the 5 weeks prior to screening or in the 4 weeks prior to the lipid qualifying visit at Week -1;
- •4. Have been adherent to an appropriate diet for at least 8 weeks;
- •5. Females who are post-menarche must not be pregnant or breast feeding and, if sexually active, must be using a reliable form of contraception; and
- •6. Written informed consent and assent (if necessary) obtained as required per local regulations.
- •Are the trial subjects under 18? yes
- •Number of subjects for this age range: 96
- •F.1.2 Adults (18-64 years) no
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) no
- •F.1.3.1 Number of subjects for this age range
排除标准
- •1. Unable or unwilling to take study drug;
- •2. Fasting TG >400 mg/dL (4.5 mmol/L);
- •3. Homozygous familial hypercholesterolaemia;
- •4. Other secondary causes of hyperlipidaemia (eg, hypothyroidism, human immunodeficiency virus infection, systemic lupus erythematosus, organ transplantation, previous malignancy, nephrotic syndrome, glycogen storage disease);
- •5. Previous history of statin intolerance, adverse effects with other statin use, or hypersensitivity to any components of the study drug;
- •6. Need for non-statin lipid-lowering medications;
- •7. Apheresis therapy;
- •8. Use of any concomitant medication which may interfere with the objectives of the study;
- •9. Type 1 diabetes mellitus;
- •10. Poorly controlled type 2 diabetes mellitus defined as haemoglobin A1c >9.0% at screening;
- •11. Severe renal impairment defined as serum creatinine >2.0 mg/dL at screening;
- •12. Uncontrolled hypertension;
- •13. Untreated thyroid disease;
- •14. Severe hepatic impairment, active liver disease, or persistent elevation of alanine transaminase or aspartate transaminase >3 × the upper limit of normal (ULN);
- •15. Active muscle disease or creatine kinase >3 × ULN (unless explained by exercise);
- •16. Screening laboratory values within the following age/gender appropriate reference ranges as assessed by the central laboratory:
- •Haemoglobin <10 g/dL for males or <9 g/dL for females or
- •Alkaline phosphatase >2 × ULN for age;
- •17. Any other laboratory abnormality that could compromise patient safety because of study participation;
- •18. Malignancy during the past 5 years;
- •19. Current smoker or history of drug or alcohol abuse;
- •20. Hospitalisation for any cause within 30 days prior to the administration of study drug;
- •21. History of major surgery in the 3 months prior to screening;
- •22. Any medical condition which, in the judgment of the Investigator, would jeopardize the evaluation of safety and/or constitute a significant safety risk to the patient; or
- •23. Participation in another clinical study involving an investigational drug during the course of this study or within 30 days prior to signing the informed consent/assent form for this study.
研究者
相似试验
进行中（未招募）
不适用
A Randomised, Double-Blind, Placebo-Controlled, Parallel Group, Phase II study to Assess the efficacy of 28 Day Oral Administration of AZD1236 in Adult Patients with Cystic Fibrosis.Estudio fase II de distribución aleatoria, doble ciego, controlado con placebo y de grupos paralelos, para evaluar la eficacia de la administración oral durante 28 días de AZD1236 a pacientes adultos con fibrosis quística - CYBERCystic FibrosisFibrosis quísticaMedDRA version: 9.1Level: LLTClassification code 10011763Term: Cystic fibrosis lungEUCTR2008-004699-34-ESAstraZeneca AB50
进行中（未招募）
不适用
A Randomised, Double-Blind, Placebo-Controlled, Parallel-group, Multicentre, 24 week Study to Evaluate the Efficacy and Safety of Transdermal Testosterone (300 mcg/day) in Naturally Menopausal Women with Hypoactive Sexual Desire Disorder Receiving Systemic Transdermal Estrogen, Oral Non-Conjugated Equine Estrogen, or No Estrogen Therapy - ADOREHypoactive sexual desire disorderEUCTR2006-001179-39-DEProcter & Gamble Pharmaceuticals270
进行中（未招募）
不适用
A Randomised, Double-Blind, Placebo-Controlled, Parallel-Group Study to Assess Long Term (one year) Efficacy and Safety Study of Tiotropium Inhalation Solution 5µg (2 puffs of 2.5µg) Delivered by the Respimat Inhaler in Patients with Chronic Obstructive Pulmonary Disease (COPD)EUCTR2006-001009-27-HUBoehringer Ingelheim Pharma GesmbH3,000
进行中（未招募）
不适用
A Randomised, Double-Blind, Placebo-Controlled, Parallel-Group, Multi-centre, Dose Ranging Study to Evaluate the Efficacy and Safety of Losmapimod (GW856553) Tablets Administered Twice Daily compared with Placebo for 24 Weeks in Adult Subjects with Chronic Obstructive Pulmonary Disease (COPD).EUCTR2010-019695-76-EEGlaxoSmithKline Research & Development675
进行中（未招募）
不适用
A Randomised, Double-Blind, Placebo-Controlled, Parallel Group, Multicentre, Long-Term Study to Evaluate the Safety of Once-Daily, Intranasal Administration of GW685698X Aqueous Nasal Spray 100mcg for 52 Weeks in Adult and Adolescent Subjects with Perennial Allergic RhinitisPerennial allergic rhinitisEUCTR2004-000091-14-LTGlaxoSmithKline736